hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06355180 id: Shoudufazhan2024-1-2122 briefTitle: Esketamine Treatment for Depressive Episodes With Suicidal Ideation in Mood Disorders overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-12 date: 2026-12 date: 2024-04-09 date: 2024-04-09 name: Capital Medical University class: OTHER name: Wuhu Fourth People's Hospital name: The Second People's Hospital of Dali Bai Autonomous Prefecture name: Inner Mongolia Autonomous Region Mental Health Center name: Beijing Chaoyang District Third Hospital name: Beijing Daxing District Xinkang Hospital name: Capital's Funds for Health Improvement and Research briefSummary: This study is a multicenter, non-inferiority, randomized, parallel-group, open-label clinical trial aimed at evaluating the effectiveness of esketamine versus modified electroconvulsive therapy (MECT) in treating suicidal ideation during depressive episodes of mood disorders. Additionally, it seeks to explore the potential mechanisms of esketamine's anti-suicidal effects. conditions: Mood Disorders conditions: Suicidal Ideation conditions: Depressive Episode studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Patients will be randomized to either the esketamine group or the MECT group, but due to the differences in treatment modalities, it will not be possible to blind the subjects and investigators. To ensure the objectivity of the measurements, independent assessors will be established. These assessors are psychiatrists trained in the consistency of the scales and will remain blinded to the group allocation of the subjects throughout the entire assessment process. whoMasked: OUTCOMES_ASSESSOR count: 340 type: ESTIMATED name: Subanesthetic dose intravenous esketamine name: Modified electroconvulsive therapy measure: Suicide remission rate based on the Scale for Suicidal Ideation (SSI) measure: Quick Inventory of Depressive Symptoms Self Report (QIDS-SR) measure: Columbia Suicide Severity Rating Scale (CSSR-S) measure: Montgomery Asberg Depression Rating Scale (MADRS) measure: Clinical Global Impressions(CGI) measure: Short Form 12 Health Survey(SF-12) measure: Sheehan Disability Scale(SDS) measure: Digital Span Test(DST) measure: Digit Symbol Substitution Test(DSST) measure: Perceived Deficit Questionnaire for Depression 5-item(PDQ-D-5) measure: Young Mania Rating Scale (YMRS) measure: Clinician Administered Dissociative States Scale(CADSS) measure: Adverse event sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06355167 id: Bacoxy_I briefTitle: Effect of Oral Intake of Bacopa Monneiri on Vascular Oxidative Stress acronym: Bacoxy_I overallStatus: COMPLETED date: 2022-03-15 date: 2022-05-25 date: 2022-09-30 date: 2024-04-09 date: 2024-04-10 name: Cliniques universitaires Saint-Luc- Université Catholique de Louvain class: OTHER briefSummary: Bacoxy_I study aims to evaluate the efficacy of a standardized Bacopa monnieri extract, Bacopa-400®, on vascular oxidative stress. conditions: Oxidative Stress conditions: Cardiovascular Diseases conditions: Bacopaside II conditions: Bacopa Monnieri conditions: Endothelial Dysfunction conditions: Aquaporin 1 conditions: AQP1 studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Group A (n=10): 400mg/d of Bacopa monnieri Broup B (n=10): 800 mg/d of Bacopa monnieri primaryPurpose: PREVENTION masking: NONE count: 20 type: ACTUAL name: Bacopa monnieri measure: Ex vivo DCFDA test on red blood cells (RBCs) measure: Plasma lipid peroxydes measure: Methemoglobin in red blood cells measure: Nitrosylated hemoglobin (HbNO) in red blood cells measure: haemoglobin measure: haematocrit measure: Red blood cells count measure: Sodium measure: Potassium measure: Bicarbonate measure: Total cholesterol measure: High-Density Lipoprotein (HDL) cholesterol measure: Low-Density Lipoprotein (LDL) cholesterol measure: Triglycerides measure: aspartate aminotransferase (ASAT), (U/L) measure: alanine aminotransferase (ALAT) (U/L) measure: gamma-glutamyl-transferase (GGT) level measure: Creatinine measure: Glomerular filtration rate sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Clinique universitaires saint luc city: Brussels zip: 1200 country: Belgium lat: 50.85045 lon: 4.34878 hasResults: False
nctId: NCT06355154 id: 069823- HMO-CTIL briefTitle: Effects of Moderate Carbohydrate Consumption on Metabolic and Obstetric Outcomes in Pregnant Women With Insulin-treated Diabetes- A Randomized Controlled Trial overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2027-05-01 date: 2028-02-01 date: 2024-04-09 date: 2024-04-09 name: Hadassah Medical Organization class: OTHER briefSummary: Diabetes during pregnancy increases maternal and fetal complications, necessitating optimal glycemic control. The standard care diet (SCD, ≥175g/day carbohydrate) lacks robust evidence, particularly for pregnancies requiring intensive insulin treatment (IIT). This RCT investigates whether a moderate carbohydrate diet (MCD, ≤120g/day) versus SCD improves glycemic control and alters metabolomic profiles in pregnant individuals on IIT.
Aims: To compare the efficacy and safety of a SCD versus MCD on glycemic control, metabolomic signatures, and pregnancy outcomes in pregnant individuals on IIT. conditions: Diabetes in Pregnancy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Open label, randomized controlled trial primaryPurpose: TREATMENT masking: NONE count: 120 type: ESTIMATED name: Nutritional intervention measure: Time in range measure: Time above range sex: FEMALE minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT hasResults: False
nctId: NCT06355141 id: E-15189967-050.04-494458 briefTitle: Oral Structural and Functional Problems in Children With Autism overallStatus: NOT_YET_RECRUITING date: 2024-04-11 date: 2024-05-13 date: 2024-08-12 date: 2024-04-09 date: 2024-04-09 name: Hacettepe University class: OTHER briefSummary: This study aims to examine oral structural and functional problems in children with autism. conditions: Autism Spectrum Disorder conditions: Chewing Problem conditions: Drooling studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 90 type: ESTIMATED name: oral assessment measure: Demographic Information Form measure: Time to achieve Oromotor skills measure: Oral structural assessment measure: Chewing evaluation measure: Drooling of saliva evaluation measure: Tongue thrust evaluation sex: ALL minimumAge: 5 Years maximumAge: 15 Years stdAges: CHILD hasResults: False
nctId: NCT06355128 id: 20240307 briefTitle: A Cross-sectional Study of Ocular Manifestations During the Covid-19 Pandemic in Hubei Province overallStatus: ACTIVE_NOT_RECRUITING date: 2024-01-01 date: 2024-02-18 date: 2024-04-30 date: 2024-04-09 date: 2024-04-09 name: Zhongnan Hospital class: OTHER name: Qichun People's Hospital briefSummary: To investigate the clinical features of ocular manifestations during the novel coronavirus pneumonia pandemic in Hubei at the end of 2022 conditions: COVID-19 conditions: Ocular Surface Disease studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 16000 type: ACTUAL name: NOT measure: Questionnaire data were collected and statistically analyzed. sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Zhongnan Hospital of Wuhan University city: Wuhan state: Hubei zip: 430071 country: China lat: 30.58333 lon: 114.26667 hasResults: False
nctId: NCT06355115 id: 400/218/K.3/302/2023 briefTitle: Prophylactic Antibiotics Duration Towards Healing and Risk of Infection in Permanent Pacemaker (PPM) Installation acronym: PACE-PRO overallStatus: RECRUITING date: 2023-09-01 date: 2024-09-01 date: 2024-09-01 date: 2024-04-09 date: 2024-04-09 name: University of Brawijaya class: OTHER name: Saiful Anwar Hospital briefSummary: The insertion of a permanent pacemaker (PPM) is frequently a life-saving procedure. However, the implantation process could sometimes lead to a rare but serious infection. Therefore, administering prophylactic antibiotics to prevent infections before they occur, is a useful strategy to lower the risk of such infections.
* Visit the clinic for follow-ups and tests. conditions: Pacemaker Complication studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 100 type: ESTIMATED name: Cefazolin 1000 MG Injection measure: Number of participants with early pocket infection (EPI) measure: Number of participants with late pocket infection (LPI) measure: Number of participants with infective endocarditis (IE) measure: Number of participants who underwent pacemaker revision measure: Level of C-reactive protein (mg/dl) measure: Level of procalcitonin (mcg/dl) measure: Erythrocyte sedimentation rate (ESR) (mm/hour) measure: Neutrophil-to-leukocyte ratio (NLR) measure: Neutrophil count (cells/mm3) measure: Leukocyte count (cells/mm3) sex: ALL minimumAge: 18 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT facility: RSUD Dr. Saiful Anwar status: RECRUITING city: Malang state: Jawa Timur zip: 65112 country: Indonesia name: RSUD Dr. Saiful Anwar role: CONTACT phone: 0341-362101 email: staf-rsu-drsaifulanwar@jatimprov.go.id lat: -7.9797 lon: 112.6304 hasResults: False
nctId: NCT06355102 id: 2024-SR-116 briefTitle: The Development of Tinnitus in Patients With SSNHL: Insights From fMRI and Metabolomics overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2025-12-31 date: 2026-03-31 date: 2024-04-09 date: 2024-04-09 name: The First Affiliated Hospital with Nanjing Medical University class: OTHER briefSummary: The goal of this clinical trial is to investigate the factors and mechanisms underlying tinnitus generation and chronification in patients with sudden sensorineural hearing loss (SSNHL) . The main questions it aims to answer are:
Investigators will compare the brain functional states and serum metabolite profiles of patients with SSNHL and tinnitus to those without tinnitus. Morever, tinnitus symptom characteristics, audiological outcomes, and brain functional states will be assessed during time. conditions: Sudden Sensorineural Hearing Loss conditions: Tinnitus studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 90 type: ESTIMATED measure: Brain function states measure: Serum metabolomics sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06355089 id: VAR-MIKRO briefTitle: Intestinal Microbiota: Immunity, Recovery and Metabolic Health acronym: VAR-MIKRO overallStatus: COMPLETED date: 2023-01-09 date: 2023-09-07 date: 2023-09-07 date: 2024-04-09 date: 2024-04-09 name: University of Turku class: OTHER name: Government Body Funding briefSummary: The aim of this intervention study is to investigate the effect of a specific postbiotic (Lacticaseibacillus rhamnosus GG = LGG) and whey protein on immunity, recovery, and weight management in young adults. The objective is based on previous knowledge about the health-promoting effects of these factors. A new goal is to study the combined effect of the postbiotic and whey protein. The results of the study can be utilized to promote the health of the young adults. conditions: Healthy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 160 type: ACTUAL name: Placebo Comparator name: Whey protein hydrolysate milk product name: Postbiotic and whey protein hydrolysate milk product measure: Concentrations of inflammatory markers from the blood samples measure: Gut microbiota composition in feces measure: Weight of the participant measure: Waist circumference of the participant measure: Infections during the intervention measure: Development of physical fitness measure: Sleep quality measure: Recovery measure: Blood pressure measure: BMI sex: ALL minimumAge: 17 Years maximumAge: 28 Years stdAges: CHILD stdAges: ADULT facility: University of Turku city: Turku country: Finland lat: 60.45148 lon: 22.26869 hasResults: False
nctId: NCT06355076 id: CSZ03 briefTitle: New Urethral Reconstruction in Robot-assisted Laparoscopic Radical Resection overallStatus: RECRUITING date: 2023-02-05 date: 2026-06 date: 2026-06 date: 2024-04-09 date: 2024-04-09 name: Qilu Hospital of Shandong University class: OTHER briefSummary: The purpose of this clinical trial is to compare new reconstruction and anastomosis in robot-assisted radical laparoscopic resection It will also understand the possibility of exploring new reconstruction in completely solving patients' postoperative urinary incontinence The main questions it aims to answer are:
The intervention group adopted the new reconstruction proposed by our team; End-to-end anastomosis was performed in non-intervention group. conditions: Prostate Cancer studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The experimental group received a new urethral reconstruction technique, which involves suturing the levator ani muscle with the lateral striated muscle of the urethra, the dorsal median ridge (MDR), and the Di's fascia together for continuous suturing before performing bladder urethral anastomosis. After the reconstruction is completed, the end to end anastomosis of the bladder urethra is performed primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Patients in the experimental or control group, as well as their family members, are unaware whoMasked: PARTICIPANT count: 94 type: ESTIMATED name: New urethral reconstruction measure: Recovery of urinary incontinence measure: complication measure: PSA measure: recurrence sex: MALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Qilu hospital status: RECRUITING city: Jinan state: Shandong zip: 276600 country: China name: shouzhen chen role: CONTACT phone: 18560089085 email: 201900412102@mail.sdu.edu.cn lat: 36.66833 lon: 116.99722 hasResults: False
nctId: NCT06355063 id: NP-PCF-037 briefTitle: CellFX® nsPFA™ Cardiac Surgery System to Treat Atrial Fibrillation overallStatus: NOT_YET_RECRUITING date: 2024-05-15 date: 2025-08-31 date: 2025-10-31 date: 2024-04-09 date: 2024-04-09 name: Pulse Biosciences, Inc. class: INDUSTRY briefSummary: This feasibility study will be conducted to demonstrate the initial safety and effectiveness of the CellFX® nsPFA™ Cardiac Clamp in performing a box lesion around the 4 pulmonary veins as an isolated procedure or as a part of a more extensive surgical ablation set in conjunction with concomitant cardiac surgical procedure. conditions: Atrial Fibrillation conditions: Surgery studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: This study is a prospective, multicenter, single arm, non-randomized, feasibility study. primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: CellFX® nsPFA™ Cardiac Surgery System measure: Rate of acute major adverse events (MAEs) measure: Number of Participants with acute electrical isolation of the bilateral pulmonary veins and left atrial free wall. measure: Proportion of Participants with one or more SAEs measure: Number of Participants with Long-Term Technical Success sex: ALL minimumAge: 22 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Academic Medical Center city: Amsterdam country: Netherlands lat: 52.37403 lon: 4.88969 facility: Maastricht University Medical Center city: Maastricht country: Netherlands lat: 50.84833 lon: 5.68889 facility: St. Antonius Hospital city: Nieuwegein country: Netherlands lat: 52.02917 lon: 5.08056 hasResults: False
nctId: NCT06355050 id: UKJ-ultraHART briefTitle: Ultrahypofractionated, Adaptive Radiation Therapy of Prostate Cancer acronym: ultraHART overallStatus: NOT_YET_RECRUITING date: 2024-06-30 date: 2026-09-30 date: 2031-09-30 date: 2024-04-09 date: 2024-04-09 name: Jena University Hospital class: OTHER name: University Hospital Schleswig-Holstein name: Klinikum Stuttgart briefSummary: In this prospective, multi-center cohort study, the tolerability and quality of life during ultrahypofractionated radiotherapy (RT) of early stage prostate cancer is surveyed at several institutions in Germany. Radiotherapy is delivered with by an online-adaptive RT device (Varian Ethos), which is able to correct daily variations in anatomy and to adjust the irradiation plan accordingly. A digital patient questionnaire is used to asses quality of life longitudinally. Quality of life (QoL) and toxicity profiles will be correlated with planning parameters and compared to retrospective cohorts of patients who underwent normofractionated RT or moderately hypofractionated RT, respectively. conditions: Prostate Cancer conditions: Adaptive Radiotherapy conditions: Quality of Life studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 100 type: ESTIMATED measure: Toxicity (CTCAE v5.0) measure: Quality of Life (EPIC 26) measure: Planning parameters measure: Dose constraints measure: Conformity indices measure: Quality of adaptive planning measure: PSA-value measure: Overall survival measure: Recurrence free survival sex: MALE minimumAge: 18 Years maximumAge: 120 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Radiotherapy and Radiation Oncology, Jena University Hospital city: Jena country: Germany name: Klaus Pietschmann, MD role: CONTACT email: klaus.pietschmann@med.uni-jena.de name: Georg Wurschi, MD role: PRINCIPAL_INVESTIGATOR lat: 50.92878 lon: 11.5899 hasResults: False
nctId: NCT06355037 id: B2024.1.30 briefTitle: Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer overallStatus: NOT_YET_RECRUITING date: 2024-04-10 date: 2024-12-31 date: 2025-01-31 date: 2024-04-09 date: 2024-04-09 name: Fudan University class: OTHER briefSummary: This is a Phase II, open-label, single-arm study evaluating the efficacy and safety of combined treatment of dasatinib, quercetin with chemotherapy in mTNBC (triple negative breast cancer) patients who progressed during previous chemotherapy. conditions: Triple-negative Breast Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 10 type: ESTIMATED name: Quercetin name: Dasatinib name: Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum measure: Objective Response Rate (ORR) measure: Disease Control Rate (DCR) measure: Progression Free Survival (PFS) measure: Safety and treatment-related AEs measure: Biomarker analysis1 measure: Biomarker analysis2 sex: FEMALE minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06355024 id: A2024.1.30 briefTitle: Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer overallStatus: NOT_YET_RECRUITING date: 2024-04-10 date: 2024-12-31 date: 2025-01-31 date: 2024-04-09 date: 2024-04-09 name: Fudan University class: OTHER briefSummary: This is a Phase II, open-label, single-arm study evaluating the efficacy and safety of combined treatment of Inosine with chemotherapy in mTNBC (triple negative breast cancer) patients who progressed during previous chemotherapy. conditions: Triple-negative Breast Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 10 type: ESTIMATED name: Inosine name: Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum measure: Objective Response Rate (ORR) measure: Disease Control Rate (DCR) measure: Progression Free Survival (PFS) measure: Biomarker analysis1 measure: Safety and treatment-related AEs sex: FEMALE minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06355011 id: 7016194 briefTitle: Total Elbow Replacement in England: Analysis of National Joint Registry and Hospital Episode Statistics Data overallStatus: COMPLETED date: 2024-03-01 date: 2024-04-02 date: 2024-04-02 date: 2024-04-09 date: 2024-04-09 name: University of Manchester class: OTHER name: The National Joint Registry name: The Royal College of Surgeons of England name: John Charnley Trust name: University of Bristol briefSummary: The goal of this observational registry study is to provide detailed descriptions of the patients who are receiving primary total elbow replacement surgery in England. The main questions it aims to answer are:
Pseudonymous data from the National Joint Registry NJR of all patients with total elbow replacement will be used. conditions: Total Elbow Replacement studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 3891 type: ACTUAL name: Total Elbow Replacement measure: The incidence of total elbow replacement (TER) in England measure: Serious adverse events or re-admissions measure: Duration of elective wait measure: Post-operative duration of stay measure: Surgeon volume measure: Hospital volume measure: Patient characteristics (Age) measure: Body mass index measure: Hand dominance measure: American Society of Anaesthesiologists (ASA) grade measure: Indication for total elbow replacement measure: Socioeconomic status measure: Ethnicity measure: Co-morbidities measure: Charlson Comorbidity Index measure: Implant classification measure: Fixation type measure: Implant type measure: If radial head replacement was used measure: Grade of primary surgeon measure: Funding measure: Elective admission type sex: ALL minimumAge: 18 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Centre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre city: Manchester zip: M13 9PT country: United Kingdom lat: 53.48095 lon: -2.23743 hasResults: False